Completed PHASE1/PHASE2 INTERVENTIONAL NCT00088062

STA-5326 in Crohn's Disease Patients

A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450

Sponsor: Synta Pharmaceuticals Corp.

Interventions STA-5326

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Feb 29, 2004 Completion: Nov 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Crohn's Disease and is currently completed. Synta Pharmaceuticals Corp. leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Synta Pharmaceuticals Corp.

Data source: Synta Pharmaceuticals Corp.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altoona, United States , Anaheim, United States , Boston, United States , Charlotte, United States , Chicago, United States , Great Neck, United States , Memphis, United States , Nashville, United States , North Miami Beach, United States , Portland, United States and 5 more locations